본문 바로가기
KERD
논문KCI 등재

Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective

Nguyen Tram T. T.|Kim Yoon Tae|Jeong Geunyeol|Jin Mirim
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2024.12|Experimental and Molecular Medicine|제56권 |pp. 559-569|DOI 10.1038/s12276-024-01182-6

1

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS) is a life-threatening immune disorder triggered by rheumatic disease, infections, malignancies, or medications. Characterized by the presence of hemophagocytic macrophages and a fulminant cytokine storm, sHLH/MAS leads to hyperferritinemia and multiorgan failure and rapidly progresses to death. The high mortality rate and the lack of specific treatments necessitate the development of a new drug. However, the complex and largely unknown immunopathologic mechanisms of sHLH/MAS, which involve dysfunction of various immune cells, diverse etiologies, and different clinical contexts make this effort challenging. This review introduces the terminology, diagnosis, and clinical features of sHLH/MAS. From a translational perspective, this review focuses on the immunopathological mechanisms linked to various etiologies, emphasizing potential drug targets, including key molecules and signaling pathways. We also discuss immunomodulatory biologics, existing drugs under clinical evaluation, and novel therapies in clinical trials. This systematic review aims to provide insights and highlight opportunities for the development of novel sHLH/MAS therapeutics.

Abstract

Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS) is a life-threatening immune disorder triggered by rheumatic disease, infections, malignancies, or medications. Characterized by the presence of hemophagocytic macrophages and a fulminant cytokine storm, sHLH/MAS leads to hyperferritinemia and multiorgan failure and rapidly progresses to death. The high mortality rate and the lack of specific treatments necessitate the development of a new drug. However, the complex and largely unknown immunopathologic mechanisms of sHLH/MAS, which involve dysfunction of various immune cells, diverse etiologies, and different clinical contexts make this effort challenging. This review introduces the terminology, diagnosis, and clinical features of sHLH/MAS. From a translational perspective, this review focuses on the immunopathological mechanisms linked to various etiologies, emphasizing potential drug targets, including key molecules and signaling pathways. We also discuss immunomodulatory biologics, existing drugs under clinical evaluation, and novel therapies in clinical trials. This systematic review aims to provide insights and highlight opportunities for the development of novel sHLH/MAS therapeutics.

참고문헌 (117)

  1. McGonagle, D., "Immune cartography of macrophage activation syndrome in the COVID-19 era", Nat. Rev. Rheumatol, 17, pp.145~157 (2021)
  2. Goransdotter Ericson, K., "Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis", Am. J. Hum. Genet, 68, pp.590~597 (2001)
  3. Ramos-Casals, M., "Adult haemophagocytic syndrome", Lancet, 383, pp.1503~1516 (2014)
  4. Grom, A. A., "Macrophage activation syndrome in systemic juvenile rheumatoid arthritis", J. Pediatr, 129, pp.630~632 (1996)
  5. Borgia, R. E., "Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus", Arthritis Rheumatol, 70, pp.616~624 (2018)
  6. Garcia-Pavon, S., "Kawasaki Disease Complicated With Macrophage Activation Syn drome : A Systematic Review", J. Pediatr. Hematol. Oncol, 39, pp.445~451 (2017)
  7. Arlet, J. B., "Reactive haemophagocytic syndrome in adult-onset Still’s dis ease : a report of six patients and a review of the literature", Ann. Rheum. Dis, 65, pp.1596~1601 (2006)
  8. Henter, J. I., "HLH-2004 : Diagnostic and therapeutic guidelines for hemo phagocytic lymphohistiocytosis", Pediatr. Blood Cancer, 48, pp.124~131 (2007)
  9. Fardet, L., "Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome", Arthritis Rheumatol, 66, pp.2613~2620 (2014)
  10. Parodi, A., "Macrophage activation syndrome in juvenile systemic lupus erythematosus : a multinational multicenter study of thirty-eight patients", Arthritis Rheum, 60, pp.3388~3399 (2009)
  11. Ravelli, A., "2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis : A European League Against Rheumatism", American College of Rheumatology, Arthritis Rheumatol, pp.2016, 68[DOI]
  12. Minoia, F., "Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis", Ann. Rheum. Dis, 78, pp.1357~1362 (2019)
  13. Rouphael, N. G., "Infections associated with haemophagocytic syndrome", Lancet Infect. Dis, 7, pp.814~822 (2007)
  14. Khan, H. H., "Report of a Fatal Case of Hemophagocytic Lymphohistiocytosis Syndrome and a Review of the Literature", Cureus, 12, pp.e12049~ (2020)
  15. Andersson, U., "Hyperinflammation : On the pathogenesis and treatment of macrophage activation syndrome", Acta Paediatr, 110, pp.2717~2722 (2021)
  16. Behrens, E. M., "Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice", J. Clin. Invest, 121, pp.2264~2277 (2011)
  17. Lounder, D. T., "Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe con current infections", Blood Adv, 3, pp.47~50 (2019)
  18. Brisse, E., "Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders", Cyto kine Growth Factor Rev, 26, pp.263~280 (2015)
  19. Keohane, E. M., "Rodak’s hematology : clinical principles and applications" (2020), Elsevier
  20. Ruscitti, P., "H-ferritin and CD68(+)", H-ferritin(+)monocytes, Clin. Exp. Immunol, pp.2016, 186[DOI]
  21. Pham, C. G., "Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species", Cell, 119, pp.529~542 (2004)
  22. Ruscitti, P., "Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still’s disease, developing macrophage activation syndrome, correlate with the severity of the disease", Autoimmun. Rev, 14, pp.429~437 (2015)
  23. Billiau, A. D., "Macrophage activation syndrome: characteristic findings on liver biopsy illus trating the key role of activated, IFN-gamma-producing lymphocytes and IL-6and TNF-alpha-producing macrophages", Blood, 105, pp.1648~1651 (2005)
  24. Crayne, C. B., "The Immunology of Macrophage Activation Syndrome", Front Immunol, 10, pp.119~ (2019)
  25. Grunfeld, C., "Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat", J. Lipid Res, 30, pp.579~585 (1989)
  26. Lin, F. C., "IFN-gamma causes aplastic anemia by altering hematopoietic stem", progenitor cell composition and disrupting lineage differentiation, 2014, pp.124, 3699~3708
  27. Yin, G., "The prognostic role of plasma fibrinogen in adult secondary hemophagocytic lymphohistiocytosis", Orphanet J. Rare Dis, 15, pp.332~ (2020)
  28. Cassidy, J. T., "Textbook of pediatric rheumatology E-Book" (2010), Elsevier Health Sciences
  29. Ramamoorthy, S., "Corticosteroids : Mechanisms of Action in Health and Disease", Rheum. Dis. Clin. North Am, 42, pp.15~31 (2016)
  30. Ambrose, A. R., "Synaptic secretion from human natural killer cells is diverse and includes supramolecular attack particles", Proc. Natl Acad. Sci. USA, 117, pp.23717~23720 (2020)
  31. Zamai, L., "Natural killer(NK)cell-mediated cytotoxicity : differential use of TRAIL and Fas ligand by immature and mature primary human NK cells", J. Exp. Med, 188, pp.2375~2380 (1998)
  32. Carter, S. J., "Macrophage activation syndrome in adults : recent advances in pathophysiology, diagnosis and treatment", Rheu matol. (Oxf. ), 58, pp.5~17 (2019)
  33. Noval Rivas, M., "Kawasaki disease : pathophysiology and insights from mouse models", Nat. Rev. Rheumatol, 16, pp.391~405 (2020)
  34. Villanueva, J., "Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syn drome", Arthritis Res Ther, 7, pp.R30~R37 (2005)
  35. Zhou, J., "Natural killer cell activity and frequency of killer cell immunoglobulin-like receptors in children with different forms of juvenile idiopathic arthritis", Pediatr. Allergy Immunol, 24, pp.691~696 (2013)
  36. Shimojima, Y., "Characteristics of Circulating Natural Killer Cells and Their Interferon-gamma Production in Active Adult-onset Still Disease", J. Rheumatol, 46, pp.1268~1276 (2019)
  37. Vastert, S. J., "Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis", Rheumatol. (Oxf.), 49, pp.441~449 (2010)
  38. Johnson, T. S., "Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis", J. Immunol, 192, pp.84~91 (2014)
  39. Havari, E., "Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro", Immunology, 141, pp.123~131 (2014)
  40. Jenkins, M. K., "Effects of cyclosporine A on T cell development and clonal deletion", Science, 241, pp.1655~1658 (1988)
  41. Gothe, F., "Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency", J. Allergy Clin. Immunol, 150, pp.955~964 (2022)
  42. Platanias, L. C., "Mechanisms of type-I-and type-II-interferon-mediated signalling", Nat. Rev. Immunol, 5, pp.375~386 (2005)
  43. Arend, W. P., "IL-1, IL-18, and IL-33 families of cytokines", Immunol. Rev, 223, pp.20~38 (2008)
  44. de Jager, W., "Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis : a cross-sectional study", Ann. Rheum. Dis, 66, pp.589~598 (2007)
  45. Mazodier, K., "Severe imbalance of IL-18", IL-18BP in patients with secondary hemophagocytic syndrome, 2005, pp.106, 3483~3489
  46. Takakura, M., "Transient natural killer cell dysfunction associated with interleukin-18 overproduction in systemic juvenile idiopathic arthritis", Pediatr. Int, 60, pp.984~985 (2018)
  47. Weiss, E. S., "Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome", Blood, 131, pp.1442~1455 (2018)
  48. Yasin, S., "IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome", Rheumatol. (Oxf.), 59, pp.361~366 (2020)
  49. Canna, S. W., "Life-threatening NLRC4-associated hyperinflammation success fully treated with IL-18 inhibition", J. Allergy Clin. Immunol, 139, pp.1698~1701 (2017)
  50. Jiang, W., "Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis", J. Immunol, 187, pp.781~790 (2011)
  51. Bielekova, B., "Regulatory CD56(bright)natural killer cells mediate immu nomodulatory effects of IL-2Ralpha-targeted therapy(daclizumab)in multiple sclerosis", Proc. Natl Acad. Sci. USA, 103, pp.5941~5946 (2006)
  52. Lanier, L. L., "The origin and functions of natural killer cells", Clin. Immunol, 95, pp.S14~S18 (2000)
  53. Robbins, S. H., "Natural killer cells promote early CD8 T cell responses against cytomegalovirus", PLoS Pathog, 3, pp.e123~ (2007)
  54. Benson, D. M. Jr, "A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed", Refractory Multiple Myeloma, 2015, pp.21, 4055~4061
  55. Weitzman, S., "Approach to hemophagocytic syndromes", Hematol. Am. Soc. Hematol. Educ. Program, 2011, pp.178~183 (2011)
  56. Bracaglia, C., "Macrophage Activation Syndrome : different mechanisms leading to a one clinical syndrome", Pediatr. Rheumatol. Online J, 15, pp.5~ (2017)
  57. Shrestha, B., "Report of a Fatal Pediatric Case of Hemophagocytic Lymphohistiocytosis Associated with Pandemic Influenza A(H1N1)Infection in 2009", Pediatr. Neonatol, 56, pp.189~192 (2015)
  58. De Matteis, A., "Expansion of CD4dimCD8+ T cells characterizes macro phage activation syndrome and other secondary HLH", Blood, 140, pp.262~273 (2022)
  59. Lee, J. S., "The type I interferon response in COVID-19 : implications for treatment", Nat. Rev. Immunol, 20, pp.585~586 (2020)
  60. Otsuka, R., "Macrophage activation syndrome and COVID-19", Inflamm. Regen, 40, pp.19~ (2020)
  61. Macaraeg, M., "Complications of complications : diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis", RMD Open, 9, pp.e002611~ (2023)
  62. Zehr, B., "Differentiating fulminant EBV infection complicated by HLH from Lymphoma : report of a case and a brief literature review", Diagn. Pathol, 18, pp.28~ (2023)
  63. Miyawaki, T., "Expression of CD45R0(UCHL1)by CD4+ and CD8+ T cells as a sign of in vivo activation in infectious mononucleosis", Clin. Exp. Immunol, 83, pp.447~451 (1991)
  64. Yaqinuddin, A., "Appli cation of intravenous immunoglobulin(IVIG)to modulate inflammation in cri tical COVID-19-A theoretical perspective", Med Hypotheses, 151, pp.110592~ (2021)
  65. Milone, M. C., "Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy", Blood, 105, pp.994~996 (2005)
  66. Fox, A., "Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses", PLoS One, 7, pp.e31535~ (2012)
  67. Terrell, C. E., "Perforin deficiency impairs a critical immunor egulatory loop involving murine CD8(+)T cells and dendritic cells", Blood, 121, pp.5184~5191 (2013)
  68. Prieto-Perez, L., "Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage in COVID-19 infection", Mod. Pathol, 33, pp.2139~2146 (2020)
  69. Mehta, P., "COVID-19 : consider cytokine storm syndromes and immuno suppression", Lancet, 395, pp.1033~1034 (2020)
  70. Papatriantafyllou, M., "Cytokines : GM-CSF in focus", Nat. Rev. Immunol, 11, pp.370~371 (2011)
  71. Tan, Y., "Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19", Cell Discov, 7, pp.42~ (2021)
  72. Min, Y. Q., "Immune evasion of SARS-CoV-2 from interferon antiviral system", Comput Struct. Biotechnol. J, 19, pp.4217~4225 (2021)
  73. Hung, I. F., "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial", Lancet, 395, pp.1695~1704 (2020)
  74. Bosteels, C., "Loss of GM-CSF-dependent instruction of alveolar macro phages in COVID-19 provides a rationale for inhaled GM-CSF treatment", Cell Rep. Med, 3, pp.100833~ (2022)
  75. Bonaventura, A., "Targeting GM-CSF in COVID-19 Pneumonia : Rationale and Strategies", Front Immunol, 11, pp.1625~ (2020)
  76. Karakike, E., "Macrophage Activation-Like Syn drome : A Distinct Entity Leading to Early Death in Sepsis", Front Immunol, 10, pp.55~ (2019)
  77. Singer, M., "The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)", JAMA, 315, pp.801~810 (2016)
  78. Lennartz, M., "Molecular mechanisms of macrophage Toll-like recep tor-Fc receptor synergy", F1000Res, 7, pp.21~ (2018)
  79. van Egmond, M., "Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity", Immunol. Rev, 268, pp.311~327 (2015)
  80. Gorelik, M., "Hypocomplementemia associated with macrophage activation syndrome in systemic juvenile idiopathic arthritis and adult onset still’s disease : 3 cases", J. Rheumatol, 38, pp.396~397 (2011)
  81. Ramanan, A. V., "Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis", J. Rheumatol, 30, pp.401~403 (2003)
  82. Sjoelund, V., "Phosphoproteome profiling of the macrophage response to different toll-like receptor ligands identifies differences in global phosphorylation dynamics", J. Proteome Res, 13, pp.5185~5197 (2014)
  83. Bruhns, P., "Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease", Immunity, 18, pp.573~581 (2003)
  84. Shang, L., "Selective antibody intervention of Toll-like receptor 4 activation through Fc gamma receptor tethering", J. Biol. Chem, 289, pp.15309~15318 (2014)
  85. Delavigne, K., "Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy", Haematologica, 99, pp.474~480 (2014)
  86. Teachey, D. T., "Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy", Blood, 121, pp.5154~5157 (2013)
  87. Ishii, K., "Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients", J. Clin. Invest, 130, pp.5425~5443 (2020)
  88. Xiao, X., "Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies", J. Exp. Clin. Cancer Res, 40, pp.367~ (2021)
  89. Bertheloot, D., "Necroptosis, pyroptosis and apoptosis : an intricate game of cell death", Cell Mol. Immunol, 18, pp.1106~1121 (2021)
  90. Mucha, S. R., "Management and Prevention of Cellular-Therapy Related Toxicity: Early and Late Complications", Curr. Oncol, 30, pp.5003~5023 (2023)
  91. Rejeski, K., "Immune Effector Cell-Associated Hematotoxicity(ICAHT) : EHA", EBMT Consensus Grading and Best Practice Recommendations, 2023, pp.142, 865~877
  92. Gust, J., "Endothelial Activation and Blood-Brain Barrier Disruption in Neu rotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells", Cancer Discov, 7, pp.1404~1419 (2017)
  93. Jatiani, S. S., "Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra", Clin. Lymphoma Myeloma Leuk, 20, pp.632~636 (2020)
  94. Norelli, M., "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells", Nat. Med, 24, pp.739~748 (2018)
  95. Kelly, A., "A case of macrophage activation syndrome successfully treated with anakinra", Nat. Clin. Pr. Rheumatol, 4, pp.615~620 (2008)
  96. Lind-Holst, M., "High-dose anakinra as treat ment for macrophage activation syndrome caused by refractory Kawasaki dis ease in an infant", BMJ Case Rep, 12, pp.e229708~ (2019)
  97. Bindoli, S., "Intravenous anakinra to curb cytokine storm in adult-onset Still’s disease and in macrophage activation syndrome : A case series", Jt. Bone Spine, 90, pp.105524~ (2023)
  98. Ajeganova, S., "Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still’s disease: when dosage matters in overcoming secondary therapy resistance", Ther. Adv. Mus culoskelet. Dis, 12, pp.1759720X20974858~ (2020)
  99. Verbsky, J. W., "Effective use of the recombinant interleukin 1receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis", J. Rheumatol, 31, pp.2071~2075 (2004)
  100. Baker, R., "Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab", Clin. Rheumatol, 38, pp.603~608 (2019)
  101. Papa, R., "Successful treatment of refractory hyperferritinemic syndromes with canakinumab : a report of two cases", Pediatr. Rheumatol. Online J, 18, pp.56~ (2020)
  102. Olin, R. L., "Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis", Am. J. Hematol, 83, pp.747~749 (2008)
  103. Lee, J. H., "A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still’s Disease With Tocilizumab", J. Rheuma. Dis, 29, pp.123~128 (2022)
  104. Watanabe, E., "Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still’s Disease : A Case-Based Review", Case Rep. Med, 2016, pp.5656320~ (2016)
  105. Chellapandian, D., "Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome", Front Pediatr, 11, pp.1123104~ (2023)
  106. Gabr, J. B., "Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still’s disease : case report and review of the literature", Ann. Transl. Med, 8, pp.887~ (2020)
  107. Prahalad, S., "Etanercept in the treatment of macrophage activation syndrome", J. Rheumatol, 28, pp.2120~2124 (2001)
  108. Maeshima, K., "Adult-onset Still’s disease with macrophage activation syn drome successfully treated with a combination of methotrexate and etanercept", Mod. Rheumatol, 22, pp.137~141 (2012)
  109. Rivera-Rodriguez, L., "Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease", J. Pediatr. Hematol. Oncol, 43, pp.e448~e451 (2021)
  110. Lackner, H., "Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children", Haematologica, 93, pp.291~294 (2008)
  111. Levy, O., "Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease", Eur. J. Rheumatol, 9, pp.217~220 (2022)
  112. Yi, G., "Case Report : Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis", Front Immunol, 13, pp.914265~ (2022)
  113. Junga, Z., "Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus", BMJ Case Rep, pp.bcr2017221347~ (2017)
  114. Kishida, D., "Macrophage activation syndrome in adult dermatomyositis : a case-based review", Rheumatol. Int, 40, pp.1151~1162 (2020)
  115. Record, J. L., "Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis : a ret rospective case series", J. Rheumatol, 38, pp.180~181 (2011)
  116. Eloseily, E. M., "Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis", Arthritis Rheumatol, 72, pp.326~334 (2020)
  117. Kyriazopoulou, E., "Macrophage activation-like syndrome : an immunological entity associated with rapid progression to death in sepsis", BMC Med, 15, pp.172~ (2017)

관련 논문AI추천

A retrospective analysis of etiology and outcomes of hemophagocytic lymphohistiocytosis in children and adults도영록, 심예지, 이재민, 허미화, Abraham Kwak, Heung Sik Kim, Hyun Ji Lim, Nani Jung영남대학교 의과대학 · Journal of Yeungnam Medical Science2021 · 제38권 제3호Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis조덕, 김석진, 김선희, 김희진, 박민승, 유인영대한진단검사의학회 · Annals of Laboratory Medicine2019 · 제39권 제5호성인 혈구탐식증후군 환자들의 원인과 사망에 관련된 요인권기태, 김능수, 김신우, 김혜인, 류성열, 이종명, 장현하, 허지안대한감염학회 · Infection and Chemotherapy2012 · 제44권 제2호류마티스 관절염 환자에서 발생한 혈구탐식성 림프조직구증송영욱, 이은봉, 이은영, 최인아대한내과학회 · 대한내과학회지2014 · 제86권 제3호Higher Fatality for Severe Fever with Thrombocytopenia Syndrome Complicated by Hemophagocytic Lymphohistiocytosis어영, 김영근, 김주원, 김효열, 안광진, 정인영, 최준용연세대학교의과대학 · Yonsei Medical Journal2019 · 제60권 제6호Hemophagocytic Lymphohistiocytosis after Lung Transplantation장준, 김세규, 김송이, 김영삼, 박무석, 백효채, 정경수, 정준원, Ah Young Leem, M.D., Sung Woo Moon대한중환자의학회 · Acute and Critical Care2015 · 제30권 제1호

이 간행물의 다른 논문 (218건)

Big data and deep learning for RNA biologyJeon Hyeonseong, Baek Daehyun, Hwang Hyeonseo, Yeo Nagyeongpp. 1-29RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinomaXu Yanan, Ke Shanjia, Lu Shounan, Bai Miaoyu, Yu Hongjun, Yin Bing, Wang Chaoqun, Feng Zhigang, Li Zihao, Huang Jingjing, Li Xinglong, Qian Baolin, Hua Yongliang, Fu Yao, Sun Bei, Wu Yaohua, Ma Yongpp. 1-14Molecular mechanisms of circular RNA translationKim Yoon Ki, Hwang Hyun Jungpp. 1-9The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolismKim Ho, Yun Hye Jin, 이종호, Lee Su Bin, Kim Seok-Ho, Park Yun-Yong, Park Su Hwan, Ju Jin-Sung, Woo Hyunmin, Győrffy Balázs, Kim Eun-jeong, Han Hee Dong, Eyun Seong-ilpp. 1-15Neuron type-specific optogenetic stimulation for differential stroke recovery in chronic capsular infarctKim Ra Gyung, Cho Jongwook, Park Ji-Young, Kim Young Ro, Lee Min-Cheol, Kim Hyoung-Ihlpp. 1-11
원문 보기